Ross Marchand is Executive Director of TPA. Ross is an alumnus of the Mercatus Center MA Fellowship at George Mason University and a graduate of the University of Virginia School of Law. He has worked on a variety of legal matters, including the Alaska-Hawaiian airline merger and the United States Postal Service v. Konan Supreme Court case. He has also authored policy briefs on a variety of issues, including multiple analyses on the legal and policy issues facing the Food and Drug Administration. His work has appeared in numerous publications including The Wall Street Journal, National Review, Forbes, The Denver Post, and the Washington Examiner.
Topics
Appearances (2)
2026-05-05
The Taxpayers Protection Alliance’s Ross Marchand Discusses FDA Drug Approval Challenges and SolutionsIn the Health Policy Podcast episode featuring Ross Marchand, Executive Director of the Taxpayers Protection Alliance, the discussion centers on the challenges and inefficiencies of the FDA drug approval process. Marchand highlights a report titled "Blocking Breakthroughs," which reveals increasing rejection rates for medications and rising evaluation costs, emphasizing the need for regulatory reforms to improve patient access to life-saving drugs. Recommendations include regulatory reciprocity with international agencies and provisional approvals for medications that meet safety but not efficacy thresholds.
2026-01-21
Taxpayers Protection Alliance Executive Director Ross Marchand Discusses the Flaws of the 340B Drug Pricing ProgramIn the latest episode of the Health Policy Podcast, Ross Marchand, Executive Director of the Taxpayers Protection Alliance, discusses the flaws of the 340B Drug Pricing Program. He highlights how the program, intended to provide discounted drugs to hospitals, has led to increased costs for taxpayers and patients as hospitals often do not pass on savings. Marchand advocates for reducing government involvement in healthcare to improve cost and quality.
Notable quotes
“Whenever you have these complicated laws and these outta control regulations, everyone loses.”
“What has actually been happening with the 340B program is it's being abused.”
“You have a program that has noble intentions, but is failing because of these unintended consequences.”
“If a program is beyond repair, that is the only solution at the end of the day.”
“Whenever you have all this control and whenever you have all this regulation... the prices are gonna go up and the quality is going to stagnate.”
“The government is far too involved in healthcare, and unless government gets outta the way, costs will continue to climb and quality will continue to stagnate.”
“The FDA is always shifting the goalposts and they are always making up new excuses to deny patients access.”
“Unfortunately, there's a lot of bureaucratic inertia.”
“Every time there's an approval and then something bad happens, it gets extensively reported on.”
“The FDA is going to squander that with heavy handed rules and not allowing patients access.”
“If a drug is good enough to get approval in those countries and those jurisdictions, it should be good enough for US approval.”
“Patients are worthy of making this decision. These drugs can tremendously benefit patient lives, but you have to give them that choice to begin with.”
